Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;34(4):254-259.
doi: 10.1080/08880018.2017.1360971. Epub 2017 Oct 17.

Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition

Abhishek Bavle  1   2 , Jeremy Jones  3   2 , Frank Y Lin  1   2 , Amy Malphrus  4   2 , Adekunle Adesina  5   2 , Jack Su  1   2
Affiliations

Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition

Abhishek Bavle et al. Pediatr Hematol Oncol. 2017 May.

Abstract

While clinical and radiographic responses to agents targeting the mitogen-activated protein kinases (MAPK) pathway have been repor-ted in pediatric low-grade gliomas (LGG), early phase trials indicate refractoriness to these medications in some of these patients. We report a patient with disseminated LGG with the BRAFV600E mutation, which was refractory to selumetinib, a MEK inhibitor, but subsequently showed immediate clinical and radiographic response to dabrafenib, a BRAF inhibitor, with sustained effect for 9 months prior to clinical progression. In LGGs, treatment resistance to one agent targeting the MAPK pathway might not imply refractoriness to other agents targeting this pathway.

Keywords: BRAF inhibitor; MAPK pathway; MEK inhibitor; dabrafenib; low-grade glioma.

PubMed Disclaimer

MeSH terms